Ardsley Advisory Partners’s Arcadia Biosciences RKDA Stock Holding History

Ardsley Advisory Partners’s Portfolio RKDA Stock Details RKDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-38,163	Closed	-$3.16M	–	151
2021 Q3	$3.16M	Buy	38,163 +13,138	+52%	+$1.23M	0.48%	44
2021 Q2	$2.97M	Buy	+25,025	New	+$2.73M	0.35%	56
2021 Q1	–	Sell	-7,508	Closed	-$759K	–	164
2020 Q4	$759K	Buy	7,508 +6,882	+1,099%	+$840K	0.12%	89
2020 Q3	$70K	Buy	+626	New	+$84.5K	0.01%	140
2020 Q1	–	Sell	-2,503	Closed	-$548K	–	151
2019 Q4	$548K	Buy	+2,503	New	+$502K	0.09%	100
2018 Q3	–	Sell	-626	Closed	-$206K	–	178
2018 Q2	$206K	Buy	+626	New	+$342K	0.03%	143

Other funds holding RKDA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Ardsley Advisory Partners's RKDA Position: Q4 2021 in Review

Ardsley Advisory Partners sold out of Arcadia Biosciences (RKDA) in Q4 2021, closing a stake of 38,163 shares — an estimated $3.16M sold.

Ardsley Advisory Partners first reported a position in RKDA in Q2 2018 and held it in 6 quarters. The position peaked at $3.16M in Q3 2021. 27 funds tracked by Wall St. Rank hold RKDA as of Q4 2021.

Ardsley Advisory Partners reported no remaining Arcadia Biosciences position as of Q4 2021 after selling out during the quarter.
Ardsley Advisory Partners sold 38,163 Arcadia Biosciences shares in Q4 2021, an estimated $3.16M.
Ardsley Advisory Partners first reported a position in Arcadia Biosciences in Q2 2018 and held it in 6 quarters.
Ardsley Advisory Partners's Arcadia Biosciences position peaked at $3.16M in Q3 2021.
27 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q4 2021.

Based on Ardsley Advisory Partners's 13F filing for Q4 2021, filed 14 Feb 2022.